We are live on ! Find out more
WP

Waycross Partners Portfolio holdings

AUM $1.05B
1-Year Est. Return 20.92%
This Fund
S&P 500
This Quarter Est. Return
+10.5%
1 Year Est. Return
+20.92%
3 Year Est. Return
+78.91%
5 Year Est. Return
+114.23%
10 Year Est. Return
–
AUM
$461M
AUM Growth
+$117M
Cap. Flow
+$81.3M
Cap. Flow %
17.64%
Top 10 Hldgs %
41.02%
Holding
99
New
12
Increased
35
Reduced
15
Closed
4

Top Buys

Rank Stock Value
1
TGT icon
Target
TGT
+$13.3M
2
HUM icon
Humana
HUM
+$12M
3
TMO icon
Thermo Fisher Scientific
TMO
+$10.7M
4
AAPL icon
Apple
AAPL
+$5.41M
5
MSFT icon
Microsoft
MSFT
+$4.78M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$9.98M
2
ADBE icon
Adobe
ADBE
+$6.4M
3
ELAN icon
Elanco Animal Health
ELAN
+$2.14M
4
CSL icon
Carlisle Companies
CSL
+$1.33M
5
MRVL icon
Marvell Technology
MRVL
+$1.32M

Sector Composition

Rank Sector Weight
1 Technology 26.06%
2 Healthcare 20.03%
3 Consumer Discretionary 15.74%
4 Financials 15%
5 Industrials 8.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AAPL icon
1
Apple
AAPL
$4.89T
$29.7M 6.44%
153,019
+31,028
+25% +$5.41M
MSFT icon
2
Microsoft
MSFT
$2.98T
$26.1M 5.67%
76,745
+15,240
+25% +$4.78M
NVDA icon
3
NVIDIA
NVDA
$5.02T
$22.1M 4.8%
523,240
+35,410
+7% +$1.18M
META icon
4
Meta Platforms (Facebook)
META
$1.69T
$19.1M 4.14%
66,419
+9,201
+16% +$2.27M
ISRG icon
5
Intuitive Surgical
ISRG
$142B
$18.7M 4.07%
54,823
+8,689
+19% +$2.63M
AMZN icon
6
Amazon
AMZN
$2.69T
$17.1M 3.7%
130,826
+30,348
+30% +$3.47M
ABBV icon
7
AbbVie
ABBV
$449B
$14.8M 3.22%
110,096
+18,433
+20% +$2.7M
TJX icon
8
TJX Companies
TJX
$171B
$14M 3.03%
164,903
+27,437
+20% +$2.16M
ULTA icon
9
Ulta Beauty
ULTA
$20.6B
$13.8M 2.98%
29,225
+6,075
+26% +$2.98M
GOOGL icon
10
Alphabet (Google) Class A
GOOGL
$4.33T
$13.7M 2.97%
114,409
+21,513
+23% +$2.48M
SBUX icon
11
Starbucks
SBUX
$124B
$13.4M 2.92%
135,721
+26,338
+24% +$2.73M
TGT icon
12
Target
TGT
$63.7B
$13.3M 2.89%
101,096
+89,378
+763% +$13.3M
ADI icon
13
Analog Devices
ADI
$185B
$12.4M 2.69%
63,752
+13,077
+26% +$2.42M
EW icon
14
Edwards Lifesciences
EW
$50.6B
$11.7M 2.54%
123,935
+27,144
+28% +$2.36M
MA icon
15
Mastercard
MA
$487B
$11.7M 2.53%
29,682
+4,366
+17% +$1.64M
CSCO icon
16
Cisco
CSCO
$432B
$11.3M 2.44%
217,498
+25,151
+13% +$1.24M
HUM icon
17
Humana
HUM
$46.4B
$11M 2.39%
24,653
+23,753
+2,639% +$12M
GS icon
18
Goldman Sachs
GS
$323B
$11M 2.39%
34,171
+6,616
+24% +$2.18M
MRVL icon
19
Marvell Technology
MRVL
$169B
$10.7M 2.32%
179,045
-27,135
-13% -$1.32M
CSX icon
20
CSX Corp
CSX
$94.6B
$10.7M 2.32%
313,265
+101,492
+48% +$3.21M
TMO icon
21
Thermo Fisher Scientific
TMO
$202B
$10.3M 2.24%
+19,775
New +$10.7M
V icon
22
Visa
V
$694B
$9.74M 2.11%
40,998
+11,819
+41% +$2.71M
JPM icon
23
JPMorgan Chase
JPM
$912B
$9.06M 1.97%
62,299
+13,409
+27% +$1.84M
SYY icon
24
Sysco
SYY
$39.3B
$8.94M 1.94%
120,525
+30,045
+33% +$2.22M
NSC icon
25
Norfolk Southern
NSC
$75.9B
$8.64M 1.88%
38,116
+8,337
+28% +$1.77M
1
2 3 4

Similar funds

RC
Randolph Company Cincinnati, Ohio $1.05B AUM 35.91% 1-Year Est. Return
LPC
Long Pond Capital New York $1.05B AUM 16.49% 1-Year Est. Return
ANBT
American National Bank & Trust Wichita Falls, Texas $1.05B AUM 25.3% 1-Year Est. Return
HWCM
Hudson Way Capital Management Dallas, Texas $1.05B AUM 6.84% 1-Year Est. Return
AA
Apriem Advisors Irvine, California $1.05B AUM 22.09% 1-Year Est. Return
AAIM
Asset Advisors Investment Management Augusta, Georgia $1.05B AUM 12.32% 1-Year Est. Return
CIA
CCM Investment Advisers Columbia, South Carolina $1.04B AUM 40.82% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.05B AUM 19.14% 1-Year Est. Return

Waycross Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Waycross Partners held 99 positions worth $461M, up 34% from $344M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Waycross Partners deployed $81.3M of net new capital in Q2 2023, opening 12 new positions and adding to 35 existing holdings. Its largest new stake was Thermo Fisher Scientific: 19,775 shares worth $10.3M.

By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Eli Lilly, an estimated $9.98M trimmed.

  • Waycross Partners's largest Q2 2023 buy was Thermo Fisher Scientific: 19,775 shares worth $10.3M.
  • Waycross Partners added most to Target in Q2 2023, an estimated $13.3M increase.
  • Waycross Partners's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $9.98M.
  • Waycross Partners fully exited Elanco Animal Health in Q2 2023, selling an estimated $2.14M.
  • Waycross Partners's ten largest holdings make up 41% of its $461M portfolio in Q2 2023.
  • Waycross Partners opened 12 new positions and closed 4 in Q2 2023.
  • Waycross Partners's portfolio value rose 34% quarter-over-quarter to $461M.

Based on Waycross Partners's 13F filing for Q2 2023, filed 26 Jul 2023.